Cargando…
Randomized, placebo‐controlled trial of ADS‐5102 (amantadine) extended‐release capsules for levodopa‐induced dyskinesia in Parkinson's disease (EASE LID 3)
BACKGROUND: The treatment of levodopa‐induced dyskinesia in Parkinson's disease (PD) is an unmet need with no approved drug therapy. OBJECTIVE: The purpose of this study was to investigate the efficacy and safety of 274 mg ADS‐5102 (amantadine) extended‐release capsules (equivalent to 340‐mg am...
Autores principales: | Oertel, Wolfgang, Eggert, Karla, Pahwa, Rajesh, Tanner, Caroline M., Hauser, Robert A., Trenkwalder, Claudia, Ehret, Reinhard, Azulay, Jean Philippe, Isaacson, Stuart, Felt, Larissa, Stempien, Mary Jean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763269/ https://www.ncbi.nlm.nih.gov/pubmed/28833562 http://dx.doi.org/10.1002/mds.27131 |
Ejemplares similares
-
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study
por: Hauser, Robert A., et al.
Publicado: (2017) -
Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015) -
Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102
por: Isaacson, Stuart H., et al.
Publicado: (2018) -
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease
por: Tanner, Caroline M., et al.
Publicado: (2020) -
Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2018)